4//SEC Filing
Bernstein Harold 4
Accession 0002050172-26-000006
CIK 0001842295other
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 4:51 PM ET
Size
9.4 KB
Accession
0002050172-26-000006
Insider Transaction Report
Form 4
Bernstein Harold
President, R&D & CMO
Transactions
- Exercise/Conversion
Common Stock
2026-01-07$10.42/sh+25,156$262,126→ 25,156 total - Sale
Common Stock
2026-01-07$40.20/sh−25,156$1,011,299→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-07−25,156→ 312,407 totalExercise: $10.42Exp: 2032-10-26→ Common Stock (25,156 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.55 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Documents
Issuer
Maze Therapeutics, Inc.
CIK 0001842295
Entity typeother
Related Parties
1- filerCIK 0002050172
Filing Metadata
- Form type
- 4
- Filed
- Jan 8, 7:00 PM ET
- Accepted
- Jan 9, 4:51 PM ET
- Size
- 9.4 KB